Investor Presentaiton

BIOND BIOLOGICS BION-206 Program Gannt MOA studies (In Vivo, Ex Vivo) Lead development (affinity maturation, engineering, Humanization) CMC + GMP production IND enabling studies (TOX, TCR, In vitro safety PK, ADA, etc...) Regulatory filing (Pre-IND, IND) Phase 1 2021 2022 2023 2024 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Pre IND IND Biond Biologics Corporate Presentation | May 2021 | Non-confidential 22

View entire presentation